TG1050

Home/TG1050

Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice

Roland Kratzer, et al. AASLD, The Liver Meeting 2018, November [...]

By |2019-07-01T15:37:57+02:00November 30th, 2018|Publication, TG1050|Comments Off on Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice

Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study

Claire Fournier, et al. AASLD, The Liver Meeting 2018, November [...]

By |2019-07-01T15:55:08+02:00November 7th, 2018|Publication, TG1050|Comments Off on Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study
Go to Top